Active, Not Recruiting
Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced Renal Cell Carcinoma After Prior Therapy - CA209-653
Aktualizováno: 18 květen, 2022 | ClinicalTrials.gov
Pohlaví
Věková skupina
Active, Not Recruiting
Inclusion Criteria: - ≥ 18 years - diagnosis of advanced RCC (confirmed by histology or cytology) - treatment decision to initiate a treatment with nivolumab for the first time for the treatment of RCC (according to the label approved in Germany) has already been taken - signed informed consent Exclusion Criteria: - diagnosis of a cancer other than advanced RCC within the past 5 years, ie, a cancer other than RCC that requires systemic or other treatment. Patients that have been treated curatively more than 5 years ago with no evidence of recurrence and prostate cancer patients in active surveillance can be included - previous treatment with nivolumab and/or ipilimumab - current active participation in an interventional clinical trial for treatment of their advanced RCC.
Důrazně doporučujeme kontaktovat BMS a oznámit vedlejší účinky / nežádoucí příhody
Zde jsou definovány vedlejší účinky / nežádoucí příhody a další příhody, které by měly být hlášeny
Nahlásit vedlejší účinky / nežádoucí příhody nebo stížnosti na kvalitu produktu: lékařské informace
